These findings were in accordance with similar studies of single-agent BV and CTCL, where patients with low CD30 expression (<10%) based on immunohistochemistry were as likely to respond as those with higher CD30 expression [23]. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.